Johnson & Johnson

corporate_fare Company Profile

Johnson & Johnson

JNJ·NYSE·Life Sciences·CIK 0000200406

Johnson & Johnson is a global healthcare company with approximately 138,200 employees worldwide. The company focuses on the research, development, manufacturing, and sale of a wide range of products primarily related to human health and well-being. Incorporated in New Jersey in 1887, Johnson & Johnson operates through its subsidiaries in virtually all countries globally. The company is structured into two main business segments: Innovative Medicine and MedTech. The Innovative Medicine segment concentrates on several therapeutic areas. These include Oncology, addressing conditions such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer. In Immunology, the focus is on rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. Neuroscience covers mood disorders, neurodegenerative disorders, and schizophrenia. The segment also addresses Pulmonary Hypertension, specifically Pulmonary Arterial Hypertension, and Infectious Diseases like HIV/AIDS. Additionally, it covers Cardiovascular and Metabolism, including thrombosis, diabetes, and macular degeneration. Products within the Innovative Medicine segment are distributed for prescription use directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals.

Johnson & Johnson (NYSE:JNJ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 66 items for JNJ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-24, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for JNJ spans 10-Q, 8-K.

Recent high-impact activity:

J&J Sets Mid-2027 DePuy Spin as $20–22B Orthopedics Valuation Circulates; UK Clears Icotyde (2026-10-24)
Smith & Nephew Talks to Combine With J&J Orthopaedics Unit Collapse Over CEO Role (2026-10-23)
J&J Q3 EPS Craters to $0.09 on $5.5B Talc Charge; Sales Up 5.9% (2026-10-21)
J&J Beats With $25.4B Q3 Revenue, Raises FY Outlook and Plans DePuy Synthes Spin-Off (2026-10-19)
J&J Q3 Beat Overshadowed by Medtech Miss; Shares Drop 5% (2026-10-14)

Financial Snapshot

Fiscal year ended December 28, 2025

Revenue

$94.19B

Net Income

$26.8B

Diluted EPS

$11.03

Op. Cash Flow

$24.53B

Free Cash Flow

$19.7B

Gross Profit

$63.94B

Cash & Equivalents

$19.71B

Total Debt

$41.44B

Debt / Equity

0.51×

Net Margin

28.5%

Shares Outstanding

2.41B sh

Source: 10-K · filed 2026-02-11 · accession 0000200406-26-000016

Short Interest & Short Volume

1.97 days to cover

FINRA reported short interest of 16,766,729 shares in JNJ as of the October 15, 2026 settlement, a 24.0% decrease from the prior period — about 2.0 days to cover at its recent average daily volume. On October 27, 2026, 43.6% of JNJ volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,766,729 shares as of October 15, 2026

Change vs prior period▼ 24.0%

Days to cover1.97 at avg daily volume of 8,521,244

Daily short volume (FINRA facilities)43.6% of 1,870,822 shares on October 27, 2026

5-day average short volume34.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with J →

show_chartPrice Chart

Loading chart...

feed JNJ - Latest Insights

Filing Type

Date Range

JNJ

Oct 24, 2026, 3:00 AM EDT

Source: Wiseek News

Importance Score:

J&J Sets Mid-2027 DePuy Spin as $20–22B Orthopedics Valuation Circulates; UK Clears Icotyde

Price at Filing: $263.16

Real-time Price: $266.27

Change: +$3.11 (+1%)

Market Cap: $646.917B

Sentiment: Neutral

View Wiseek Article

JNJ

Oct 23, 2026, 2:37 AM EDT

Source: Reuters

Importance Score:

Smith & Nephew Talks to Combine With J&J Orthopaedics Unit Collapse Over CEO Role

Price at Filing: $268.00

Real-time Price: $266.27

Change: -$1.73 (-0.65%)

Market Cap: $646.917B

Sentiment: Neutral

View Wiseek Article

JNJ

Oct 21, 2026, 4:18 PM EDT

Filing Type: 10-Q

Importance Score:

J&J Q3 EPS Craters to $0.09 on $5.5B Talc Charge; Sales Up 5.9%

Price at Filing: $257.78

Real-time Price: $266.27

Change: +$8.49 (+3%)

Market Cap: $646.917B

Sentiment: Neutral

View Wiseek Article

JNJ

Oct 19, 2026, 7:00 AM EDT

Source: Wiseek News

Importance Score:

J&J Beats With $25.4B Q3 Revenue, Raises FY Outlook and Plans DePuy Synthes Spin-Off

Price at Filing: $253.88

Real-time Price: $266.27

Change: +$12.39 (+5%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Oct 13, 2026, 9:38 PM EDT

Source: Binance News

Importance Score:

J&J Q3 Beat Overshadowed by Medtech Miss; Shares Drop 5%

Price at Filing: $249.00

Real-time Price: $266.27

Change: +$17.27 (+7%)

Market Cap: $646.917B

Sentiment: Negative

View Wiseek Article

JNJ

Oct 13, 2026, 8:12 AM EDT

Filing Type: 8-K

Importance Score:

J&J Q3 Sales Rise 5.9% to $25.4B; Raises 2026 Guidance Despite Talc Charge

Updated Oct 13, 12:07 PM ET — J&J shares fell as MedTech revenue missed expectations despite the raised guidance.

Price at Filing: $259.46

Real-time Price: $266.27

Change: +$6.81 (+3%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Oct 13, 2026, 6:20 AM EDT

Source: Dow Jones Newswires

Importance Score:

J&J Posts 9-Cent Q3 EPS, Far Below Prior-Year Levels

Updated Oct 13, 7:08 AM ET — The talc litigation charge totaled $5.5 billion pretax for the quarter.

Price at Filing: $266.55

Real-time Price: $266.27

Change: -$0.280 (-0.11%)

Market Cap: $646.917B

Sentiment: Negative

View Wiseek Article

JNJ

Oct 13, 2026, 6:41 AM EDT

Source: Seeking Alpha

Importance Score:

J&J Tops Q3 Expectations, Raises Full-Year Adjusted EPS Guidance

Updated Oct 13, 6:52 AM ET — J&J raised FY adjusted EPS guidance to $11.05-$11.15 from $10.96-$11.11 and raised low end of sales forecast to midpoint $101.2B; MedTech s…

Price at Filing: $259.10

Real-time Price: $266.27

Change: +$7.17 (+3%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Oct 12, 2026, 5:16 PM EDT

Source: Seeking Alpha

Importance Score:

Tremfya Shows 94% Crohn's Remission at Three Years in Phase 3 Data

Price at Filing: $264.50

Real-time Price: $266.27

Change: +$1.77 (+0.67%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 25, 2026, 11:03 AM EDT

Source: Benzinga

Importance Score:

J&J's Tremfya and Carvykti Hit Key Endpoints in Psoriatic Arthritis and Myeloma Trials

Price at Filing: $270.20

Real-time Price: $266.27

Change: -$3.93 (-1%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 25, 2026, 7:44 AM EDT

Source: Reuters

Importance Score:

Tremfya Becomes First IL-23 Inhibitor to Show Spinal Pain Improvement in Axial PsA

Price at Filing: $271.28

Real-time Price: $266.27

Change: -$5.01 (-2%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 25, 2026, 7:02 AM EDT

Source: Reuters

Importance Score:

Carvykti Shows 50% Five-Year Treatment-Free Remission in Early-Line Myeloma

Price at Filing: $270.22

Real-time Price: $266.27

Change: -$3.95 (-1%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 23, 2026, 10:20 AM EDT

Source: Dow Jones Newswires

Importance Score:

J&J's Tecvayli-Darzalex Combo Shows 90% Reduction in Myeloma Progression

Price at Filing: $272.14

Real-time Price: $266.27

Change: -$5.87 (-2%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 21, 2026, 8:36 AM EDT

Source: Reuters

Importance Score:

CAPLYTA Hits Primary Endpoint in Pivotal Bipolar Mania Trial, Rapid Symptom Reduction at Week 3

Price at Filing: $270.06

Real-time Price: $266.27

Change: -$3.79 (-1%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 15, 2026, 10:27 AM EDT

Source: Reuters

Importance Score:

J&J Depression Drug Fails Mid-Stage Trial, Contineum Shares Tumble 11%

Price at Filing: $263.07

Real-time Price: $266.27

Change: +$3.20 (+1%)

Market Cap: $646.917B

Sentiment: Negative

View Wiseek Article

JNJ

Sep 13, 2026, 9:47 PM EDT

Source: Reuters

Importance Score:

J&J's Rybrevant Combo Sets Survival Record in EGFR Exon 20 NSCLC

Price at Filing: $266.20

Real-time Price: $266.27

Change: +$0.070 (+0.03%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Sep 11, 2026, 12:21 PM EDT

Source: dpa-AFX

Importance Score:

J&J's ACUVUE OASYS MAX 2-Week Lenses Get CE Mark; Axogen Buys BioCircuit for $200M

Price at Filing: $265.90

Real-time Price: $266.27

Change: +$0.375 (+0.14%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Aug 27, 2026, 4:47 AM EDT

Source: Reuters

Importance Score:

China Approves J&J's Oral Psoriasis Pill Icotrokinra

Price at Filing: $273.77

Real-time Price: $266.27

Change: -$7.50 (-3%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Aug 24, 2026, 6:32 PM EDT

Source: Reuters

Importance Score:

FDA Expands Approval for J&J's Rare Blood Disorder Drug

Price at Filing: $273.38

Real-time Price: $266.27

Change: -$7.11 (-3%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

JNJ

Aug 17, 2026, 8:33 AM EDT

Source: Reuters

Importance Score:

J&J's Monarch Quest 3 Robotic Bronchoscopy Platform Cleared by FDA

Price at Filing: $259.10

Real-time Price: $266.27

Change: +$7.17 (+3%)

Market Cap: $646.917B

Sentiment: Positive

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile

Johnson & Johnson

monitoring Financial Snapshot

Short Interest & Short Volume

show_chartPrice Chart

feed JNJ - Latest Insights

Unlock Real-Time Alerts

Financial Snapshot